PL3248969T3 - Sposób wytwarzania n-[3-(aminometylo)oksetan-3-ylo]-karbaminianowych związków pośrednich - Google Patents
Sposób wytwarzania n-[3-(aminometylo)oksetan-3-ylo]-karbaminianowych związków pośrednichInfo
- Publication number
- PL3248969T3 PL3248969T3 PL17176794T PL17176794T PL3248969T3 PL 3248969 T3 PL3248969 T3 PL 3248969T3 PL 17176794 T PL17176794 T PL 17176794T PL 17176794 T PL17176794 T PL 17176794T PL 3248969 T3 PL3248969 T3 PL 3248969T3
- Authority
- PL
- Poland
- Prior art keywords
- oxetan
- aminomethyl
- preparation
- carbamate intermediates
- carbamate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D305/06—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D305/08—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Epoxy Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2014/071331 | 2014-01-24 | ||
| PCT/EP2015/051066 WO2015110446A1 (en) | 2014-01-24 | 2015-01-21 | Process for the preparation of n-[(3-aminooxetan-3-yl)methyl]-2-(1,1-dioxo-3,5-dihydro-1,4-benzothiazepin-4-yl)-6-methyl-quinazolin-4-amine |
| EP15700600.8A EP3097098B1 (en) | 2014-01-24 | 2015-01-21 | Process for the preparation of n-[(3-aminooxetan-3-yl)methyl]-2-(1,1-dioxo-3,5-dihydro-1,4-benzothiazepin-4-yl)-6-methyl-quinazolin-4-amine |
| EP17176794.0A EP3248969B1 (en) | 2014-01-24 | 2015-01-21 | Process for the preparation of n-[3-(aminomethyl)oxetan-3-yl]carbamate intermediates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3248969T3 true PL3248969T3 (pl) | 2020-06-29 |
Family
ID=52358790
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL15700600T PL3097098T3 (pl) | 2014-01-24 | 2015-01-21 | Sposób wytwarzania n-[(3-aminooksetan-3-ylo)metylo]-2-(1,1-diokso-3,5-dihydro-1,4-benzotiazepin-4-ylo)-6-metylo-chinazolino-4-aminy |
| PL17176794T PL3248969T3 (pl) | 2014-01-24 | 2015-01-21 | Sposób wytwarzania n-[3-(aminometylo)oksetan-3-ylo]-karbaminianowych związków pośrednich |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL15700600T PL3097098T3 (pl) | 2014-01-24 | 2015-01-21 | Sposób wytwarzania n-[(3-aminooksetan-3-ylo)metylo]-2-(1,1-diokso-3,5-dihydro-1,4-benzotiazepin-4-ylo)-6-metylo-chinazolino-4-aminy |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US10005770B2 (pl) |
| EP (2) | EP3248969B1 (pl) |
| JP (1) | JP6397501B2 (pl) |
| KR (1) | KR101841866B1 (pl) |
| CN (2) | CN109879837B (pl) |
| AR (2) | AR099134A1 (pl) |
| AU (1) | AU2015208244B2 (pl) |
| BR (1) | BR112016016978B1 (pl) |
| CA (1) | CA2934225C (pl) |
| ES (2) | ES2788900T3 (pl) |
| HR (2) | HRP20200715T1 (pl) |
| IL (1) | IL245882B (pl) |
| MX (1) | MX368110B (pl) |
| MY (1) | MY176210A (pl) |
| NZ (1) | NZ721534A (pl) |
| PL (2) | PL3097098T3 (pl) |
| RU (1) | RU2664643C2 (pl) |
| SG (1) | SG11201605916QA (pl) |
| SI (2) | SI3097098T1 (pl) |
| WO (1) | WO2015110446A1 (pl) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3298017B1 (en) | 2015-05-20 | 2019-08-14 | H. Hoffnabb-La Roche Ag | Compounds for treating spinal muscular atrophy |
| WO2017009316A1 (en) | 2015-07-16 | 2017-01-19 | F. Hoffmann-La Roche Ag | Crystalline forms of n-[(3-amino-3-oxetanyl)methyl]-2-(2,3-dihydro-1,1 -dioxido-1,4-benzothiazepin-4(5 h)-yl)-6-methyl-4-quinazolinamine for the treatment of respiratory syncytial virus (rsv) infections |
| MY197231A (en) | 2015-07-22 | 2023-06-06 | Enanta Pharm Inc | Benzodiazepine derivatives as rsv inhibitors |
| AU2016353961B2 (en) | 2015-11-12 | 2019-08-29 | F. Hoffmann-La Roche Ag | Compositions for treating spinal muscular atrophy |
| CA3119019C (en) | 2015-12-10 | 2024-06-11 | Ptc Therapeutics, Inc. | Compounds and methods for treating huntington's disease |
| EP3386978B1 (en) | 2015-12-10 | 2021-01-27 | H. Hoffnabb-La Roche Ag | Bridged piperidine derivatives |
| CN108017599B (zh) * | 2016-11-04 | 2020-03-03 | 上海爱科百发生物医药技术有限公司 | [3-(胺甲基)-氧杂环丁烷-3-基]氨基甲酸对甲氧基苄酯对氯苯甲酸盐合成方法 |
| EP4151627A1 (en) | 2017-06-05 | 2023-03-22 | PTC Therapeutics, Inc. | Compounds for treating huntington's disease |
| CN111182898B (zh) | 2017-06-28 | 2024-04-16 | Ptc医疗公司 | 用于治疗亨廷顿氏病的方法 |
| CN111163838B (zh) | 2017-06-28 | 2023-03-28 | Ptc医疗公司 | 用于治疗亨廷顿氏病的方法 |
| WO2019006295A1 (en) | 2017-06-30 | 2019-01-03 | Enanta Pharmaceuticals, Inc. | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS |
| CN111386118B (zh) | 2017-09-29 | 2023-05-09 | 英安塔制药有限公司 | 作为rsv抑制剂的组合药物剂 |
| BR112020019373A2 (pt) | 2018-03-27 | 2020-12-29 | Ptc Therapeutics, Inc. | Compostos para o tratamento da doença de hutington |
| IL279688B2 (en) | 2018-06-27 | 2025-01-01 | Ptc Therapeutics Inc | Heterocyclic and heteroaryl compounds for the treatment of Huntington's disease |
| WO2020005882A1 (en) | 2018-06-27 | 2020-01-02 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
| KR20210038845A (ko) | 2018-06-27 | 2021-04-08 | 피티씨 테라퓨틱스, 인크. | 헌팅턴병 치료를 위한 헤테로아릴 화합물 |
| WO2020190935A1 (en) | 2019-03-18 | 2020-09-24 | Enanta Pharmaceuticals, Inc. | Benzodiazepine derivatives as rsv inhibitors |
| CA3139821A1 (en) | 2019-05-13 | 2020-11-19 | Ptc Therapeutics, Inc. | Compounds for treating huntington's disease |
| PH12022550783A1 (en) | 2019-10-04 | 2023-07-31 | Enanta Pharm Inc | Antiviral heterocyclic compounds |
| US11505558B1 (en) | 2019-10-04 | 2022-11-22 | Enanta Pharmaceuticals, Inc. | Antiviral heterocyclic compounds |
| WO2021083290A1 (en) | 2019-10-31 | 2021-05-06 | Shanghai Ark Biopharmaceutical Co. Ltd. | Respiratory syncytial virus fusion protein inhibitor compositions and methods for the treatment and prophylaxis of rsv diseases using the same |
| CN113149977A (zh) * | 2020-01-22 | 2021-07-23 | 苏州爱科百发生物医药技术有限公司 | 一类呼吸道合胞病毒抑制剂的合成与用途 |
| UY39032A (es) | 2020-01-24 | 2021-07-30 | Enanta Pharm Inc | Compuestos heterocíclicos como agentes antivirales |
| CN111548325A (zh) * | 2020-05-16 | 2020-08-18 | 西安都创医药科技有限公司 | 一种卤代苯并硫氮杂卓化合物的制备方法及其制备的产品及其应用 |
| CN111518055A (zh) * | 2020-05-16 | 2020-08-11 | 西安都创医药科技有限公司 | 一种苯并硫氮杂卓氧化物的制备方法及其制备的产品及其应用 |
| CN111620838A (zh) * | 2020-05-16 | 2020-09-04 | 西安都创医药科技有限公司 | 一种氯代苯并硫氮杂卓化合物的制备方法及其制备的产品及其应用 |
| CN111574475B (zh) * | 2020-06-03 | 2022-09-20 | 西安都创医药科技有限公司 | 卤代苯并硫杂卓氧化物的制备方法及其制备的产品及其应用 |
| WO2022010882A1 (en) | 2020-07-07 | 2022-01-13 | Enanta Pharmaceuticals, Inc, | Dihydroquinoxaline and dihydropyridopyrazine derivatives as rsv inhibitors |
| WO2022086840A1 (en) | 2020-10-19 | 2022-04-28 | Enanta Pharmaceuticals, Inc. | Heterocyclic compounds as anti-viral agents |
| US12612412B2 (en) | 2021-02-26 | 2026-04-28 | Enanta Pharmaceuticals, Inc. | Antiviral heterocyclic compounds |
| MX2023009961A (es) | 2021-02-26 | 2023-09-05 | Enanta Pharm Inc | Compuestos heterociclicos antivirales. |
| AR129003A1 (es) | 2022-04-07 | 2024-07-03 | Enanta Pharm Inc | Compuestos heterocíclicos antivirales |
| WO2023211997A1 (en) | 2022-04-27 | 2023-11-02 | Enanta Pharmaceuticals, Inc. | Antiviral compounds |
| EP4745139A1 (en) * | 2023-07-10 | 2026-05-20 | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. | COMPOUND FOR THE TREATMENT AND PREVENTION OF INFECTIOUS DISEASES CAUSED BY THE RESPIRATORY SYNCYTIAL VIRUS |
| WO2026149524A1 (zh) * | 2025-01-09 | 2026-07-16 | 石药集团中奇制药技术（石家庄）有限公司 | 氨基吡咯烷类衍生物及其制备方法和用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1383409A (en) * | 1972-09-09 | 1974-02-12 | Pfizer Ltd | Derivatives of 2-amino- and 4-amino-quinazoline and pharmaceutical compositions containing them |
| SE9901573D0 (sv) * | 1999-05-03 | 1999-05-03 | Astra Ab | New compounds |
| CA2516329A1 (en) * | 2003-02-21 | 2004-09-02 | Pharmacia & Upjohn Company Llc | Exo-(t-butyl 2r(+))-2-amino-7-azabicyclo[2.2.1]heptane-7-carboxylate, intermediates, and process to prepare and isolate them |
| US20050009817A1 (en) * | 2003-04-30 | 2005-01-13 | Jennifer Savoy | Substituted heteroaryls |
| DE102004045648A1 (de) * | 2004-09-21 | 2006-03-23 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Betamimetika zur Behandlung von Atemwegserkrankungen |
| JP4899385B2 (ja) * | 2005-09-06 | 2012-03-21 | 宇部興産株式会社 | ３−アミノメチルオキセタン化合物の製法 |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| JP2013534233A (ja) * | 2010-08-20 | 2013-09-02 | セルゾーム リミティッド | 選択的ｊａｋ阻害剤としてのヘテロシクリルピラゾロピリミジン類似体 |
| US8871756B2 (en) * | 2011-08-11 | 2014-10-28 | Hoffmann-La Roche Inc. | Compounds for the treatment and prophylaxis of Respiratory Syncytial Virus disease |
| JP2014530225A (ja) | 2011-10-11 | 2014-11-17 | エフ．ホフマン−ラ ロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 呼吸器合胞体ウイルス疾患の処置および予防のための化合物 |
| JP2016518421A (ja) * | 2013-05-14 | 2016-06-23 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 呼吸器合胞体ウイルス感染症の処置および予防のためのアザ−オキソ−インドール |
-
2015
- 2015-01-20 AR ARP150100146A patent/AR099134A1/es active IP Right Grant
- 2015-01-21 SI SI201531193T patent/SI3097098T1/sl unknown
- 2015-01-21 CA CA2934225A patent/CA2934225C/en active Active
- 2015-01-21 BR BR112016016978-6A patent/BR112016016978B1/pt active IP Right Grant
- 2015-01-21 KR KR1020167020106A patent/KR101841866B1/ko active Active
- 2015-01-21 JP JP2016548177A patent/JP6397501B2/ja active Active
- 2015-01-21 MX MX2016009514A patent/MX368110B/es active IP Right Grant
- 2015-01-21 SG SG11201605916QA patent/SG11201605916QA/en unknown
- 2015-01-21 MY MYPI2016702654A patent/MY176210A/en unknown
- 2015-01-21 EP EP17176794.0A patent/EP3248969B1/en active Active
- 2015-01-21 ES ES15700600T patent/ES2788900T3/es active Active
- 2015-01-21 RU RU2016133187A patent/RU2664643C2/ru active
- 2015-01-21 CN CN201910222238.1A patent/CN109879837B/zh active Active
- 2015-01-21 AU AU2015208244A patent/AU2015208244B2/en active Active
- 2015-01-21 PL PL15700600T patent/PL3097098T3/pl unknown
- 2015-01-21 CN CN201580005504.5A patent/CN106414436B/zh active Active
- 2015-01-21 ES ES17176794T patent/ES2789798T3/es active Active
- 2015-01-21 HR HRP20200715TT patent/HRP20200715T1/hr unknown
- 2015-01-21 EP EP15700600.8A patent/EP3097098B1/en active Active
- 2015-01-21 NZ NZ721534A patent/NZ721534A/en unknown
- 2015-01-21 SI SI201531184T patent/SI3248969T1/sl unknown
- 2015-01-21 PL PL17176794T patent/PL3248969T3/pl unknown
- 2015-01-21 WO PCT/EP2015/051066 patent/WO2015110446A1/en not_active Ceased
-
2016
- 2016-05-26 IL IL245882A patent/IL245882B/en active IP Right Grant
- 2016-07-21 US US15/216,501 patent/US10005770B2/en active Active
-
2018
- 2018-05-24 US US15/988,570 patent/US10253022B2/en active Active
-
2020
- 2020-03-16 AR ARP200100726A patent/AR118371A2/es unknown
- 2020-04-28 HR HRP20200680TT patent/HRP20200680T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI3248969T1 (sl) | Postopek za pripravo N-(3-(aminometil)oksetan-3-il) karbamatnih intermediatov | |
| SI3380530T1 (sl) | Izboljšan postopek za pripravo sugamadeksa in njegovih intermediatov | |
| IL250441A0 (en) | A method for the production of 5-fluoro-1h-pyrazoles starting from hexafluoropropane | |
| HUE064356T2 (hu) | Eljárás enzalutamid elõállítására új intermedier felhasználásával | |
| IL248566A0 (en) | A process for the preparation of 5-fluoro-1h-pyrazoles from hexafluoropropane | |
| GB201416678D0 (en) | Process For Synthesizing Ergothioneine And Its Intermediates | |
| ZA201805871B (en) | An improved process for the preparation of lacosamide | |
| IL255819A (en) | An improved process for the preparation of sofosbuvir and intermediates | |
| SI3565552T1 (sl) | Izboljšan postopek za pripravo rivaroksabana, ki vključuje nov intermediat | |
| ZA201808387B (en) | Improved process for the preparation of carbamates | |
| IL260661B (en) | A process for the preparation of nabivolol intermediates | |
| IL253077A0 (en) | Process and intermediates for the preparation of Fermpanel | |
| ZA201701973B (en) | Process for the preparation of halo-substituted trifluoroacetophenones | |
| IL258535A (en) | Process for the preparation of organic compounds converted into halides. | |
| GB201510544D0 (en) | New synthesis of tapentadol-hci intermediates | |
| IL237572A0 (en) | Process and intermediates for the preparation of dastinib | |
| PT3102565T (pt) | Processos para a preparação de intermediários de raltegravir | |
| HUP1500603A2 (en) | Process for the separation of 10-deacetyl baccatin iii | |
| IS2977B (is) | Aðferð til framleiðslu á milliefnum sem eru nytsamleg við nýsmíði á elúxadólíni | |
| GB201700012D0 (en) | Iodoacetylcholine synthesis method as pharmaceutical intermediates | |
| GB201711318D0 (en) | Drug intermediates o-acetaminophen synthesis method | |
| TH1501000743A (th) | กระบวนการสำหรับการสังเคราะห์ของสารมัธยันตร์ของสารปราบวัชพืช ฟลูซีโตซัลฟูรอน |